

# Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant

11 July 2017

Among patients unresponsive to an antidepressant [aripiprazole](#), further analysis including cost-effectiveness is needed to understand the net utility of this approach," the authors write.

modestly increased the likelihood of remission from depression compared to switching to the antidepressant bupropion, according to a study published by *JAMA*.

A limitation of the study was that only one antidepressant and one antipsychotic were evaluated, and the generalizability of the results to other medications is unknown.

Major depressive disorder (MDD) is a chronic, debilitating disorder that affected an estimated 16 million adults in the United States in 2015. Less than one-third of patients achieve remission with their first antidepressant. Somaia Mohamed, M.D., Ph.D., of the VA Connecticut Healthcare System, West Haven, Conn., and colleagues randomly assigned 1,522 patients at 35 U.S. Veterans Health Administration medical centers diagnosed with MDD and unresponsive to at least one antidepressant to switch to a different antidepressant ([bupropion](#); n = 511); augment current treatment with bupropion (n = 506); or augment with aripiprazole (n = 505) for 12 weeks (treatment phase) and evaluated for up to 36 weeks.

**More information:** *JAMA* (2017). [jamanetwork.com/journals/jama/.../1001/jama.2017.8036](http://jamanetwork.com/journals/jama/.../1001/jama.2017.8036)

Provided by The JAMA Network Journals

Among the [patients](#) (average age, 54 years; men, 85 percent), 75 percent completed the treatment phase. Depression remission rates at 12 weeks were 22.3 percent for the switch group, 26.9 percent for the augment-bupropion group, and 28.9 percent for the augment- aripiprazole group. Symptom improvement was greater for the augment-aripiprazole group than for either the switch group or the augment-bupropion group.

Anxiety was more frequent in the two bupropion groups.

Adverse effects more frequent in the augment-aripiprazole group included drowsiness, restlessness and weight gain."Given the small effect size and adverse effects associated with

APA citation: Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant (2017, July 11) retrieved 6 August 2022 from <https://medicalxpress.com/news/2017-07-meds-additional-med-patients-unresponsive.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*